A trial of razoxane (ICRF-159) in patients with prior therapy for Hodgkin's lymphoma.
Razoxane (ICRF-159) was administered to 11 patients with Stage IV nodular sclerosing Hodgkin's lymphoma. A weekly schedule was employed with a starting dose of 1000 mg/m2 in divided doses. The dose was escalated up to 2000 mg/m2 weekly as tolerated. One objective partial remission was observed. The toxicity of the program was quite tolerable. Further trials of razoxane in this situation are not recommended.